The diversity of diffuse large B-cell lymphoma in extranodal sites: overview and update

被引:0
作者
Judith A. Ferry
机构
[1] Massachusetts General Hospital,Department of Pathology
来源
Journal of Hematopathology | 2014年 / 7卷
关键词
B-cell lymphomas; Diffuse large B-cell lymphoma; Primary central nervous system; Extranodal; Skin; Mediastinum; EBV; HHV8;
D O I
暂无
中图分类号
学科分类号
摘要
Extranodal lymphomas are a diverse group of low and high grade neoplasms of B-, T-, and NK-cell lineage, each with characteristic sites of origin, morphology, immunophenotype, genetic features, patterns of spread, and prognosis. The diversity is sometimes seen even within a single histologic type of lymphoma. This phenomenon is especially striking in the category of diffuse large B-cell lymphoma (DLBCL). DLBCLs as classified in the WHO Classification are clinically and pathologically heterogeneous (Swerdlow et al. 2008; Stein et al. 2008). Since the publication of the most recent edition of the WHO Classification of tumours of haematopoietic and lymphoid tissues (Swerdlow et al. 2008), a number of advances in the understanding of these lymphomas have been made. This review provides an overview of extranodal DLBCLs and describes recent updates regarding these lymphomas.
引用
收藏
页码:57 / 70
页数:13
相关论文
共 332 条
  • [1] Alizadeh A(2000)Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503-511
  • [2] Eisen M(2004)Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 275-282
  • [3] Davis R(2009)Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Blood 114 2273-2279
  • [4] Hans CP(2010)B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma Am J Surg Pathol 34 327-340
  • [5] Weisenburger DD(2012)Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone J Clin Oncol 30 3452-3459
  • [6] Greiner TC(2008)Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment Leuk Lymphoma 49 43-51
  • [7] Johnson NA(2012)Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas Clin Cancer Res 18 5203-5211
  • [8] Savage KJ(2013)Primary central nervous system lymphoma Curr Treat Options Oncol 14 185-197
  • [9] Ludkovski O(2013)A systematic approach to the diagnosis of suspected central nervous system lymphoma JAMA Neurol 70 311-319
  • [10] Snuderl M(2004)Primary central nervous system posttransplant lymphoproliferative disorders Am J Clin Pathol 121 246-253